Join Clinical Trials for Healthy Volunteers in Western Australia

All Categories Healthy Participants » Australia » Western Australia

First in Human Study of ALS-002158; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1

Condition: Hepatitis C, Chronic
Interventions: Drug: ALS-002158; Drug: Placebo
Sponsors: Alios Biopharma Inc.; Alios Biopharma Inc.; Vertex Pharmaceuticals Incorporated
Recruiting - verified March 2012
Inhaled Vancomycin Tolerability, Safety and Pharmacokinetics

Conditions: Healthy; Cystic Fibrosis
Interventions: Drug: AeroVanc; Drug: IV vancomycin hydrochloride
Sponsors: Savara Inc.; Savara Inc.; INC Research Limited
Completed - verified May 2012
Safety and Immunogenicity of Novartis Meningococcal B Vaccine Formulated With OMV Manufactured at Two Different Sites, in Healthy Adolescents Aged 11-17 Years

Conditions: Meningococcal Disease; Meningococcal Meningitis
Intervention: Biological: Serogroup B meningococcal vaccine
Sponsors: Novartis; Novartis; Novartis Vaccines
Completed - verified January 2012
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers

Condition: Multiple Sclerosis, Relapsing-Remitting
Interventions: Drug: GSK2018682; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012
The Cycle Study: a Study of the Effectiveness of Cycling Exercise in Breaking the Cycle of Pregnancy Diabetes

Condition: Gestational Diabetes Mellitus
Intervention: Behavioral: Supervised home-based exercise
Sponsors: The University of Western Australia; The University of Western Australia; King Edward Memorial Hospital
Recruiting - verified March 2012
The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study

Condition: Human Papillomavirus (HPV) Type 16/18 Infections and Cervical Neoplasia.
Intervention: Biological: GSK580299 (CervarixTM)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified March 2012
Ross River Virus (RRV) Vaccine Study

Condition: Prophylaxis of Ross River Virus Infection
Intervention: Biological: Ross River Virus Vaccine
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Active, not recruiting - verified October 2011
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 181 in Healthy Subjects and Subjects With Mild to Moderate Ulcerative Colitis

Condition: Ulcerative Colitis
Intervention: Drug: Amg 181
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
An Evaluation Of Three Dose Levels Of 3-Antigen Staphylococcus Aureus Vaccine (SA3Ag) In Healthy Adults

Conditions: Bacterial Infections; Staphylococcal Vaccines; Immunotherapy, Active; Staphylococcal Skin Infections; Staphylococcal Infections
Interventions: Biological: SA3Ag vaccine; Procedure: Blood draw; Procedure: Colonization swab samples; Biological: SA3Ag followed by Placebo; Procedure: Blood draw; Procedure: Colonization swab samples; Biological: Placebo; Procedure: Blood draw; Procedure: Colonization swab samples; Biological: SA3Ag with no booster in stage 2; Procedure: Blood draw; Procedure: Colonization swab samples; Procedure: Placebo with no booster in stage 2; Procedure: Blood draw; Procedure: Colonization swab samples
Sponsors: Pfizer; Pfizer
Completed - verified August 2011
Efficacy of Etoricoxib 60 mg in Modifying Pain Hypersensitivity in People With Knee Osteoarthritis

Conditions: Osteoarthritis; Pain
Interventions: Drug: Etoricoxib (Arcoxia); Drug: Sugar pill
Sponsors: Curtin University of Technology; Curtin University of Technology; Merck
Completed - verified May 2012
Interferon Alpha Lozenges in the Prevention of Winter Colds and Flu

Condition: Upper Respiratory Tract Infections
Interventions: Drug: interferon-alpha; Other: placebo
Sponsors: Amarillo Biosciences, Inc.; Amarillo Biosciences, Inc.; Department of Health, Western Australia
Completed - verified September 2011
EU/LA Pearl Index Study - Transdermal Contraceptive Patch

Condition: Contraception
Intervention: Drug: Ethinylestradiol/Gestodene (BAY86-5016)
Sponsors: Bayer; Bayer
Completed - verified October 2011
GA Levonorgestrel Intrauterine Contraceptive System (LCS) Phase III Study China

Condition: Contraception
Intervention: Drug: Levonorgestrel IUS (LCS, BAY86-5028)
Sponsors: Bayer; Bayer
Active, not recruiting - verified March 2012
Dominantly Inherited Alzheimer Network (DIAN)

Condition: Alzheimer's Disease
Intervention:
Sponsors: Washington University School of Medicine; Washington University School of Medicine; National Institute on Aging (NIA)
Recruiting - verified October 2011
Safety Study of CSL Limited's Influenza Virus Vaccine in the Paediatric Population Aged >= 6 Months to < 18 Years

Condition: Influenza
Interventions: Biological: CSL Limited Influenza Virus Vaccine; Biological: CSL Limited Influenza Virus Vaccine; Biological: CSL Limited Influenza Virus Vaccine
Sponsors: CSL Limited; CSL Limited
Completed - verified August 2011
A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Condition: Meningitis, Meningococcal
Interventions: Biological: meningococcal B rLP2086 vaccine.; Biological: meningococcal B rLP2086 vaccine.; Biological: meningococcal B rLP2086 vaccine.; Other: normal saline (placebo)
Sponsors: Pfizer; Pfizer
Active, not recruiting - verified April 2012
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to < 24 Month-Old Children and in 2 Month Old Infants

Conditions: Respiratory Syncytial Virus (RSV); Parainfluenza Virus Type 3 (PIV3)
Interventions: Biological: MEDI-534; Biological: MEDI-534; Biological: MEDI-534; Biological: MEDI-534; Biological: MEDI-534; Biological: Placebo
Sponsors: MedImmune LLC; MedImmune LLC
Active, not recruiting - verified May 2012
A Prospective Study to Examine the Effectiveness and Safety of Antivirals in Volunteers Who Receive Short-term Prophylaxis Against Pandemic Influenza

Condition: Pandemic Influenza
Intervention:
Sponsors: Kirby Institute; Kirby Institute; National Health and Medical Research Council, Australia
Withdrawn - verified April 2012
A Prospective Study to Examine the Effectiveness and Safety of Neuraminidase Inhibitors in Volunteers Who Receive Long-term Prophylaxis Against Pandemic Influenza: PIPET B

Condition: Pandemic Influenza
Intervention:
Sponsors: Kirby Institute; Kirby Institute; National Health and Medical Research Council, Australia
Withdrawn - verified April 2012
A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults

Condition: Influenza
Interventions: Biological: CSL Limited Influenza Vaccine; Biological: Placebo
Sponsors: CSL Limited; CSL Limited
Completed - verified August 2011
Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

Conditions: Meningococcal Infection; Haemophilus Infection
Interventions: Biological: Haemophilus influenzae type b and meningococcal serogroup C (vaccine); Biological: Priorix™; Biological: Hiberix™; Biological: Meningitec™
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified September 2011
Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older

Condition: Prophylaxis for HPV Infections and Associated Cervical Neoplasia
Interventions: Biological: Cervarix; Biological: Placebo control
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Active, not recruiting - verified February 2012
Human Papilloma Virus Vaccine Safety and Immunogenicity Trial in Young Adolescent Women With GSK Bio HPV-16/18.

Conditions: Human Papillomavirus (HPV) Infection; Cervical Neoplasia
Intervention: Biological: HPV-16/18 L1/AS04
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified March 2012
Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18

Conditions: Human Papillomavirus (HPV) Infection; Cervical Neoplasia
Interventions: Biological: Cervarix™; Biological: Havrix™-based investigational formulation
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Completed - verified February 2012
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy

Condition: Leukemia
Interventions: Drug: asparaginase; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: gemtuzumab ozogamicin; Drug: methotrexate; Drug: mitoxantrone hydrochloride; Procedure: allogeneic bone marrow transplantation
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010
Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia

Condition: Leukemia
Interventions: Biological: filgrastim; Drug: asparaginase; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Drug: imatinib mesylate; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: vincristine sulfate; Procedure: allogeneic bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: radiation therapy
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Completed - verified November 2010